Introduction
Metabolic syndrome refers to a clustering of established (i.e. 'traditional') and emerging (i.e. 'nontraditional') cardiovascular disease (CVD) risk factors within a single individual [Matfin, 2009; Grundy, 2007; Fonseca, 2000] . Both the established risk factors, such as obesity, diabetes, dyslipidemia, and hypertension, and other 'nontraditional' risk factors are closely related to central obesity (especially intra-abdominal adiposity, which is also known as visceral obesity) [Matfin, 2009; Grundy, 2007; Lawlor et al. 2006; Fonseca, 2000] . The emerging risk factors include dysfunction of inflammation, coagulation, platelets, fibrinolysis, lipoproteins, endothelium, and miscellaneous biological processes [Fonseca, 2000] . Individuals may develop these factors in different orders, at different severities, and at different ages [Lawlor et al. 2006] .
The underlying pathophysiology of the metabolic syndrome is considered to be related to central obesity and insulin resistance [Matfin, 2009; Grundy, 2007; Reaven, 2006] . Although the exact cause of the metabolic syndrome is not known, the association with obesity is very compelling. Adipocytes are the source of a number of important factors involved in a wide range of processes related to the features of the metabolic syndrome, including glucose and lipid metabolism, inflammation, and thrombosis (e.g. nonesterified fatty acids [NEFAs] , adiponectin, leptin, visfatin, and plasminogen activator inhibitor type 1 [PAI-1]) [Iozzo, 2009; Kershaw and Flier, 2004] . With obesity, the outputs of all of these products are higher except for adiponectin, which is abnormally low. Excess release of NEFAs predisposes to ectopic fat accumulation in liver, muscle, and visceral adipose tissue stores and can result in abnormal function (termed 'lipotoxicity'), including insulin resistance. Adipocyte hypertrophy (large adipocytes are more insulin resistant than smaller ones and secrete more pro-inflammatory adipocytokines) [O'Connell et al. 2010] , visceral adiposity, and ectopic fat accumulation (this combination has been termed 'adiposopathy' or 'sick fat' by Bays in the US [Bays, 2009] ) may result in the adverse metabolic and immune consequences that contribute to major CVD risk factors (e.g. glucose intolerance, high blood pressure [BP] , and dyslipidemia).
Insulin resistance is also considered an important factor in the etiology of this syndrome [Grundy, 2007; Lawlor et al. 2006; Reaven, 2006 Reaven, , 1988 . Insulin resistance can be defined in several ways, but is essentially an impaired biological response to insulin actions in the insulin-responsive tissues (i.e. liver, fat, and skeletal muscle) [Reaven, 2006] . However, despite the potential utility of having all of the CVD risk factors under an umbrella diagnosis of the metabolic syndrome, debate continues about its very existence [Cameron et al. 2009; Preiss and Sattar, 2009; Ferrannini, 2007; Pratley, 2007; Alberti and Zimmet, 2006; Kahn et al. 2005] . This debate is (in part) related to lack of a universally accepted definition of this state, but also to doubts regarding the need for these disparate CVD risk determinants to be 'lumped' together under one 'artificial' diagnostic heading. Is the utility of the metabolic syndrome simply related to its value as an aide-mémoire for physicians to consider other CVD risk factors when confronted with a patient with one or more of these factors?
Despite the controversies regarding the metabolic syndrome, this subject remains one of the most discussed and written about by both the lay public and healthcare professionals alike. For example, the term 'metabolic syndrome' results in almost 3 million hits on Google (this does not include all of the different permutations such as 'therapy', 'criteria', etc.) and about 30,000 results on PubMed (accessed 24 April 2010). In addition, the component risk factors include some of the most common and serious public health challenges facing both the developed and developing world today [Hossain et al. 2007] . With improvement in the economic situation in developing countries, increasing prevalence of obesity and the metabolic syndrome is seen in adults and particularly in children. The main causes are increasing urbanization, nutrition transition, and reduced physical activity [Misra and Khurana, 2008] . According to recent worldwide estimates, 1.7 billion people are classified as either overweight or obese, more than 1 billion have hypertension, and more than 500 million have either diabetes or the prediabetes category, impaired glucose tolerance (IGT) [Hossain et al. 2007] . As a consequence of these alarming figures, the prevalence of the metabolic syndrome is also (not surprisingly) very common, with almost 50 million individuals affected in the USA alone [Ford, 2005] .
In view of the incredible numbers of people affected by these chronic risk states and associated complications, pharmaceutical companies are exploring the role of existing therapies and are developing many new drugs targeting the metabolic syndrome. Indeed, one review on new therapies for the metabolic syndrome listed the number of potential 'drug targets' at nearly 10,000 (i.e. targets in the genome, proteome, transcriptome, etc.) [Flordellis et al. 2005] . However, no drugs are currently approved for the indication of metabolic syndrome [Food and Drug Administration, 2007; Heal et al. 2009 ].
Definition of metabolic syndrome
The concept of the metabolic syndrome has been around for almost 90 years [Grundy, 2007; Reaven, 2006] . Recently, increased attention has led to a number of different names being attached to this syndrome (e.g. syndrome X, insulin resistance syndrome, dysmetabolic syndrome, and Reaven syndrome), and a number of different definitions have also been proposed. Gerald Reaven, in the 1988 American Diabetes Association (ADA) Banting Lecture, drew attention to the central importance of insulin resistance in the syndrome (hence the term 'insulin resistance syndrome', i.e. relationship between resistance to insulin-mediated glucose uptake and a variety of related abnormalities and clinical syndrome) [Reaven, 1988] . Insulin resistance varies greatly between even apparently healthy persons (600-fold). Approximately 50% of this variability can be attributed to differences in adiposity (25%) and fitness (25%), with the remaining 50% probably of genetic origin [Reaven, 2006 [Reaven, , 1988 . The more insulin resistant a person, the more likely that he or she will develop some degree of glucose intolerance, dyslipidemia (i.e. hypertriglyceridemia and low high-density lipoprotein [HDL]), essential hypertension, and procoagulant and pro-inflammatory states, all of which lead to increased risk of CVD. It is unclear to what extent the components of this syndrome develop independently of each other or spring from 'common soil' genetic or other abnormalities (e.g. insulin resistance or inflammation) [Kolb and Mandrup-Paulsen, 2010; Reaven, 2006 Reaven, , 1988 . To identify persons at greater CVD risk because of these abnormalities, various bodies, including the World Health Organization (WHO), US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF), created a new diagnostic category, the metabolic syndrome [Reaven, 2006] .
The two most commonly used clinical and research definitions of the metabolic syndrome, the NCEP ATP III and IDF, are defined in Table 1 [Alberti et al. 2005; Grundy et al. 2005] .
Some of the controversy surrounding the metabolic syndrome relates to a lack of a universally accepted definition. However, there is general consensus regarding the main components of the syndrome (i.e. glucose intolerance, obesity, raised BP, and dyslipidemia), but different definitions require different cut points and have different mandatory inclusion criteria. Ultimately, the proliferation of various definitions for the metabolic syndrome reflects both the uncertainty about the etiology and different purposes for defining the syndrome [Pratley, 2007] . In each of the definitions, the presence of the syndrome is inferred from some combination of CVD risk factors. The NCEP ATP III and IDF definitions are focused on obesity, specifically waist circumference which is a measure of central obesity [Alberti et al. 2005; Grundy et al. 2005] . The IDF definition has the advantage of having specific ethnic-group-related definitions of waist circumference (i.e. Europid, Asian, etc.), although the latest reiteration for the NCEP ATP III definitions accepts a similar cut off for Asians (see Table 1 ) [Alberti et al. 2005; Grundy et al. 2005] . In comparison, the American Association of Clinical Endocrinology (AACE), WHO, and the European Study Group for Insulin Resistance (EGIR) definitions are all largely focused on insulin resistance [Grundy, 2007; Alberti and Zimmet, 2006] . Insulin resistance and hyperinsulinemia, despite having etiological importance, are not readily measured in routine clinical practice and have not been measured in many clinical studies.
Despite the added complexity of deciding on an optimal measurement or definition of insulin resistance, these various definitions should ideally be standardized, for a number of reasons. Such standardization will aid comparison of results from clinical practice, clinical trials, and drug development programs, and enable proper estimation of prevalence. The prevalence of the metabolic syndrome within individual cohorts varies with the definition used. Within each definition, the prevalence of metabolic syndrome increases with age and varies with gender and ethnicity. There is a lack of diagnostic concordance between different definitions. Only about 30% of people appear to be diagnosable by most definitions, and about 3540% of people diagnosed with metabolic syndrome are only eligible for such classification using one definition [Day, 2007] . For example, in one study the prevalence of the metabolic syndrome in the US using the IDF definition was 39%, compared with 35% using the NCEP ATP III definition [Ford, 2005] . Similar discrepancies have been observed in other populations, including Europeans [DECODE Study Group, 2006] . Interpretation of data may be further complicated by studies modifying inclusion criteria and by updates from expert groups. Using NCEP ATP III 2001 and 2005 (revised) criteria, the prevalence of metabolic syndrome in a large European diabetes cohort was 26% and 32% for men, and 23% and 29% for women, respectively [Day, 2007] .
Differences in the clustering of metabolic parameters have also been shown in different ethnic groups in developing countries. The variable clustering of the different components in the metabolic syndrome in different populations suggest varying risk clusters associated with the metabolic syndrome. For example, obesity in African-Americans is more commonly associated with hypertension, whereas obesity-related type 2 diabetes mellitus (T2DM) is more common in Hispanics. Thus, there may be combinations of the criteria of the metabolic syndrome that are more appropriate for one ethnic group than another in predicting risk of T2DM and CVD. It has been suggested that not only should the cutoffs and weighting of the criteria for the metabolic syndrome be altered for different ethnic groups in developing countries, but also that the combinations of the metabolic syndrome criteria for each ethnic group should be varied [Misra and Khurana, 2008; Day, 2007] .
Other concerns about a proper definition of metabolic syndrome relate to the choice and numbers of parameters required to diagnose metabolic syndrome, and also the thresholds for these parameters within the different definitions.
For example, in a study using the Framingham database it was shown that subjects having any two out of the five possible criteria needed to make the diagnosis of the metabolic syndrome (i.e. these subjects did not have the metabolic syndrome as defined by current criteria) were at no lesser risk of CVD than those meeting three out of five criteria (i.e. these subjects satisfied the metabolic syndrome definition , 2010; Matfin and Pratley, 2010] . However, it is anticipated that A1C will be incorporated into metabolic syndrome definitions in the near future.
It is also clear that (by definition) the current metabolic syndrome definitions are more focused on CVD risk, as opposed to diabetes risk [Buse et al. 2007 ; DECODE Study Group, 2006] . Recognition of this CVD emphasis has caused some experts and professional groups (e.g. ADA) to prefer the term cardiometabolic risk, which represents the overall risk of developing diabetes and/or CVD.
In addition, the varying definitions have different abilities to predict CVD events and death. A meta-analysis of 37 longitudinal studies suggested that the WHO-based criteria of metabolic syndrome (relative risk [RR] 2.06) was better than the NCEP ATP III-based criteria (RR 1.67) at predicting CVD events and death [Gami et al. 2007] . It is also recognized that the current sets of parameters included in the various definitions are not measuring all of the risk [Ryden et al. 2007; Lawlor et al. 2006; Grundy et al. 2005] . Indeed as much as 50% of the risk may not be captured by the current definitions. The so-called residual risk may be related to other factors such as gender, age, smoking, and also other factors associated with the metabolic syndrome (see Table 2 ), but not included in the current definitions, i.e. low-density lipoprotein (LDL), small dense LDL (sdLDL), apolipoprotein B, endothelial dysfunction, liver transaminases (reflecting nonalcoholic fatty liver disease [NAFLD] and possible complications), inflammation, plaque instability, visceral fat, prothrombotic tendency (e.g. PAI-1), measures of insulin resistance (e.g. serum insulin levels), and adiponectin. For example, we know that measurement of the inflammatory marker high-sensitivity Creactive protein (hsCRP) provides incremental risk information at all levels of the metabolic syndrome [Matfin, 2007; Lee and Pratley, 2005; Ridker et al. 2004; Ridker, 2003 ].
Based on this type of evidence, should the clinical criteria for the metabolic syndrome be expanded? This is being actively explored, but to date no additional markers have been added to the diagnostic criteria. However, it is clear that new treatments for the metabolic syndrome should also address the residual risk, and not just the traditional risk factors [Matfin, 2007; Ryden et al. 2007; Lawlor et al. 2006; Grundy et al. 2005] . It was anticipated that the long-awaited updated NCEP ATP IV guidelines (which were due to be published in March 2010, and have now been deferred until spring 2011), might have addressed some of these issues. Ironically, a recent paper by Vega and colleagues showed in a study cohort of more than 30,000 subjects that using less diagnostic criteria in an abridged ATP III definition (i.e. excluding a measure of obesity, and having three of four of the other independent risk factors as a definition of metabolic syndrome) identifies patients at higher risk of CVD [Vega et al. 2010] . This re-emphasizes the need to be cognizant of why a diagnosis of metabolic syndrome is needed in the first place (e.g. risk stratification for CVD and/or diabetes).
Controversy about the metabolic syndrome remains undiminished despite all of the thousands of articles written about this topic every year [Grundy, 2006] . Ironically, Gerald Reaven (who re-ignited interest in the 'Reaven syndrome' in 1988) recently wrote an editorial entitled 'The metabolic syndrome: is this diagnosis necessary?'. In this review he stated that the clustering of components that makes up the various definitions of metabolic syndrome is not accidental and occurs only in insulin-resistant persons [Reaven, 2006] . In addition, he concluded that diagnosing the metabolic syndrome in a person has neither pedagogical nor clinical utility, and also suggested that greater clinical emphasis should be on treating effectively any CVD risk factors that are present. Reaven also emphasized that the insulin resistance syndrome (which he first described) and metabolic syndrome (as defined by various professional bodies, e.g. IDF, NCEP ATP III) are very different. In addition, Reaven criticized the commonly used metabolic syndrome definitions, because the various components and cut offs that make up the metabolic syndrome definitions are not evidence-but consensus-based.
In defense of the metabolic syndrome, the original authors of the WHO and IDF definitions of the metabolic syndrome reiterated the importance of the recognition of obesity as the crucial element within the metabolic syndrome (as opposed to insulin resistance which Reaven believes to be paramount) [Cameron et al. 2009] . They argued that the metabolic syndrome construct is important as a risk prediction tool and is also a useful metric for monitoring the scale and progress of the global epidemic of obesity, T2DM and CVD.
However, in an invited counterview to the above article several reasons why a physician or researcher might wish to 'diagnose' a person with the metabolic syndrome were outlined [Preiss and Sattar, 2009] . These included (i) the use of metabolic syndrome as a risk prediction score (for T2DM, CVD, or both) over the short to medium term (<10 years); (ii) the use of the term to indicate increased long-term risk of T2DM and/or CVD in younger individuals; (iii) the use of the information to allow comparisons of obesity-related data in national and international studies; or (iv) to provide a simple construct that clinicians recognize to describe the features often found in obese patients. Overall, the authors concluded that the potential added value of the diagnosis of metabolic syndrome in such situations was marginal at best or even nonexistent [Preiss and Sattar, 2009 ].
Many professional groups have also entered the ongoing debate about the metabolic syndrome (e.g. existence/need/value/definition of the metabolic syndrome). Statements include 'The FDA does not necessarily consider the metabolic syndrome to represent a distinct diagnostic entity' [Food and Drug Administration, 2007] and according to the ADA and European Association for the Study of Diabetes (EASD) 'the metabolic syndrome requires more study before its designation as a syndrome is truly warranted', warning doctors against labeling patients with the term [Kahn et al. 2005] . Nevertheless, in the US a version of the metabolic syndrome (NCEP ATP III) has an ICD-9 code (277.7) which permits healthcare reimbursement [Day, 2007] .
In this issue of Therapeutic Advances in Endocrinology and Metabolism, a number of articles explore different therapeutic aspects of the metabolic syndrome (i.e. emerging drug targets; development of new therapies; and treatment of specific associations and complications, etc).
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